Detail akcie Bristol Myers online

Business Summary: Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Bristol-Myers Squibb Co revenues decreased 2% to $45.01B. Net income increased 27% to $8.03B. Revenues reflect Prioritized Brands-Revlimid segment decrease of 39% to $6.1B, Prioritized Brands-Sprycel segment decrease of 11% to $1.93B, United States segment decrease of 1% to $31.56B, other segment decrease of 16% to $699M.